Literature DB >> 7691258

Excessive production of transforming growth factor-beta by bone marrow stromal cells in B-cell chronic lymphocytic leukemia inhibits growth of hematopoietic precursors and interleukin-6 production.

L Lagneaux1, A Delforge, C Dorval, D Bron, P Stryckmans.   

Abstract

To explore the pathogenesis of marrow failure in B-cell type chronic lymphocytic leukemia (B-CLL), we have examined the production of interleukin-6 (IL-6), granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage CSF (GM-CSF) by the adherent cell population of bone marrow (BM) derived from B-CLL patients and their capacity to support hematopoietic cell proliferation. Lipopolysaccharide-stimulated B-CLL stromal cells produced G-CSF and GM-CSF in amounts similar to normal stromal layers, whereas IL-6 production was significantly decreased. Using the blast-colony forming cell assay (BI-CFC) and the classical colony-forming unit granulocyte macrophage (CFU-GM) assay, we found that: (1) marrow stromal cells of B-CLL were able to support only 25% of the BI-CFC growth supported by normal marrow stromal cells; (2) this anomaly was partially corrected by the addition of exogenous IL-6; (3) the colony-stimulating activity (CSA) of the conditioned medium (CM) of B-CLL stromal cells was lower than that of normal CM; (4) that this was the result of the presence of an inhibitor rather that of a growth factor defect; (5) this inhibition could be abrogated by addition of anti-transforming growth factor-beta (TGF-beta) neutralizing antibody; (6) this antibody corrected the deficient colony supportive activity of the B-CLL stromal cells; (7) TGF-beta production by marrow stromal cells was significantly increased in CLL compared with normal; and (8) that this was not caused by the effect of the B-CLL lymphocytes on the stromal cells. It is concluded that this increased TGF-beta production in B-CLL is probably responsible for the decreased IL-6 production by stromal cells and for the inhibiting activity on hematopoietic precursors as well. We hypothesize that TGF-beta generated at a high level by B-CLL marrow stromal cells could play a major role in the pathophysiology of the BM failure seen in advanced stages of B-CLL.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7691258

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Transforming growth factor-{beta}1 modulates responses of CD34+ cord blood cells to stromal cell-derived factor-1/CXCL12.

Authors:  Sunanda Basu; Hal E Broxmeyer
Journal:  Blood       Date:  2005-03-29       Impact factor: 22.113

2.  IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia.

Authors:  Ganchimeg Ishdorj; Erin Streu; Pascal Lambert; Harbhajan S Dhaliwal; Salaheddin M Mahmud; Spencer B Gibson; Versha Banerji; Aaron J Marshall; James B Johnston
Journal:  Blood Adv       Date:  2019-07-23

3.  The importance of IL-6 protein expression in primary human renal cell carcinoma: an immunohistochemical study.

Authors:  B Paule; J Belot; C Rudant; C Coulombel; C C Abbou
Journal:  J Clin Pathol       Date:  2000-05       Impact factor: 3.411

Review 4.  Allogeneic hematopoietic transplantation for chronic lymphocytic leukemia and lymphoma: potential for nonablative preparative regimens.

Authors:  R Champlin; S Giralt; I Khouri
Journal:  Curr Oncol Rep       Date:  2000-03       Impact factor: 5.075

Review 5.  Cytokines in the pathophysiology and treatment of chronic B-cell malignancies. A review.

Authors:  M Schuler; C Huber; C Peschel
Journal:  Ann Hematol       Date:  1995-08       Impact factor: 3.673

6.  Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patients.

Authors:  Bryce A Manso; Henan Zhang; Molly G Mikkelson; Kimberly A Gwin; Charla R Secreto; Wei Ding; Sameer A Parikh; Neil E Kay; Kay L Medina
Journal:  Leukemia       Date:  2018-10-05       Impact factor: 11.528

Review 7.  Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia.

Authors:  Jessi-F Fecteau; Thomas J Kipps
Journal:  Front Biosci (Schol Ed)       Date:  2012-01-01

8.  Chronic lymphocytic leukemia B-cell-derived TNFα impairs bone marrow myelopoiesis.

Authors:  Bryce A Manso; Jordan E Krull; Kimberly A Gwin; Petra K Lothert; Baustin M Welch; Anne J Novak; Sameer A Parikh; Neil E Kay; Kay L Medina
Journal:  iScience       Date:  2020-12-26

9.  Wogonin reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12-CXCR4/7 axis in bone marrow microenvironment.

Authors:  Hanbo Cao; Yuan Gao; Ruixuan Wang; Qinglong Guo; Hui Hui
Journal:  Ann Transl Med       Date:  2020-09

10.  Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia.

Authors:  Joanna Gora-Tybor; Jerzy Z Blonski; Tadeusz Robak
Journal:  Mediators Inflamm       Date:  2003-06       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.